Biotech

All Articles

A better check out Tough Biotech's Tough 15

.Within this week's episode of "The Best Pipe," we're diving right into Ferocious Biotech's yearly B...

Lilly faces phase 2 failure of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's celebration commemorating the commen...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of considerable management hirings, firings a...

Lykos will ask FDA to reexamine its own selection complying with being rejected of MDMA treatment for post-traumatic stress disorder

.Adhering to an unsatisfactory revealing for Lykos Rehabs' MDMA prospect for trauma at a latest FDA ...

AN 2 fifty percents roll call, stops period 3 trial after records dissatisfy

.AN2 Therapeutics is rethinking its service in response to lackluster midphase data, vowing to lay o...

Merck pays $700M for bispecific, snooping autoimmune position as well as opportunity to challenge Amgen in cancer cells

.Merck &amp Co. is actually paying for $700 million upfront to challenge Amgen in a blood cancer cel...

Gilead pays for J&ampJ $320M to go out licensing deal for seladelpar

.Along With Gilead Sciences almost an FDA decision for its liver disease drug seladelpar, the compan...

' All palms on deck' at Lilly as peers target being overweight market

.CEO David Ricks can easily observe the business putting together outdoors tents at basecamp respons...

Entero laying off team, moving out of office and stopping briefly R&ampD

.Bed mattress Liquidators has switched Entero Therapeutics white as a sheet. The financial instituti...

Exelixis drops ADC after determining it's no suit for Tivdak

.Exelixis is actually quiting on its own cells element (TF)- targeting antibody-drug conjugate after...